Liposomal Pegylated Doxorubicin versus Low-Dose Recombinant Interferon Alfa-2a in the Treatment of Advanced Classic Kaposi's Sarcoma; Retrospective Analysis of Three German Centers

By Kreuter Alexander   Rasokat Heinrich   Klouche Mariam   Esser Stefan   Bader Armin   Gambichler Thilo   Altmeyer Peter   Brockmeyer Norbert  

Cancer Investigation, Vol. 23, Iss. 8, 2005-11 ,pp. : 653-659

Informa Healthcare

Access to resources Recommend Favorite

Long-term chemotherapy of HIV-associated Kaposi's sarcoma with liposomal doxorubicin

By Hengge U.R.   Esser S.   Rudel H.-P.   Goos M.  

European Journal of Cancer, Vol. 37, Iss. 7, 2001-05 ,pp. : 878-883

Elsevier

Access to resources Recommend Favorite

Efficacy of pegylated liposomal doxorubicin in patients with advanced hepatocellular carcinoma

By Lind Pehr   Naucler Gisela   Holm Agneta   Gubanski Michael   Svensson Christer  

Acta Oncologica, Vol. 46, Iss. 2, 2007-01 ,pp. : 230-233

Informa Healthcare

Access to resources Recommend Favorite

Pegylated Liposomal Doxorubicin in Salvage Chemotherapy for Multiple Myeloma Patients

By  

Current Cancer Therapy Reviews, Vol. 9, Iss. 1, 2013-01 ,pp. : 1-7

Bentham Science Publishers

Access to resources Recommend Favorite

Phase II trial of pegylated-liposomal doxorubicin in the treatment of locally advanced unresectable or metastatic transitional cell carcinoma of the urothelial tract

By Winquist E.   Ernst D.S.   Jonker D.   Moore M.J.   Segal R.   Lockwood G.   Rodgers A.  

European Journal of Cancer, Vol. 39, Iss. 13, 2003-09 ,pp. : 1866-1871

Elsevier

Access to resources Recommend Favorite